The supply side of the COVID-19 vaccine rollout has garnered most of the attention. But a recent survey on American beliefs about the vaccines suggests that the bigger problem may be on the demand side of the equation.
The supply side of the COVID-19 vaccine rollout has garnered most of the attention. But a recent survey on American beliefs about the vaccines suggests that the bigger problem may be on the demand side of the equation.
After the pool of “enthusiastic” adults is vaccinated, vaccination rates are likely to start to plateau starting this month, according to Surgo Ventures, a behavioral science and artificial intelligence company. Because of holdouts, only about 52% of Americans will be vaccinated by July, according to Surgo’s projections — well short of the estimated 70% to 90% needed to achieve herd immunity.
The projection is based on the company’s analysis of results of a survey it conducted in March. Based on the respondents’ answers, Surgo groups them into five psychobehavioral categories: enthusiasts, watchful, cost-anxious, system distrusters and conspiracy believers. Surgo’s survey shows the proportion of respondents in the watchful and cost-anxious groups is shrinking compared with an earlier survey, but the proportion of system distrusters (7%) and conspiracy believers (16%) is about the same.
Surgo classifies system distrusters as being persuadable but says some of the conspiracy believers will need to get vaccinated if the U.S. population is to reach herd immunity. The company’s suggestions include tapping trusted figures to communicate risk-benefit ratios of vaccination and giving employees paid time off to get vaccinated.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
A Motor Neuron Mystery Points to New Potential SMA Treatment Targets
December 20th 2024Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has discovered that even in muscles that appeared resistant to SMA, subtle changes had occurred at the cellular level.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen